NEW YORK, April 19, 2018 -- Eyenovia, Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that the Company will release financial results for the first quarter ended March 31, 2018 on Wednesday, May 9, 2018, before the market opens. Following the release, Dr. Sean Ianchulev, President and Chief Executive Officer and Chief Medical Officer, and John Gandolfo, Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 am ET on Wednesday, May 9, 2018. Participants should dial 1-866-916-2921 (United States) or 1-210-874-7771 (International) with the conference code 3097559. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenoviabio.com.
After the live webcast, the event will be archived on Eyenovia’s website for one year. In addition, a telephonic replay of the call will be available until May 16, 2018. The replay can be accessed by dialing 1-855-859-2056 (United States) or 1-404- 537-3406 (International) with confirmation code 3097559.
About Eyenovia
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.
Company Contact:
Eyenovia Inc.
John Gandolfo
Chief Financial Officer
[email protected]
Investor Contact:
Tram Bui / Alexander Lobo
The Ruth Group
Phone: 646-536-7035/7037
E-mail: [email protected] / [email protected]
Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
[email protected]


Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns
SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan
Luxshare Shares Rise as First-Half Profit Jumps 18%
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook
Yindjibarndi Appeals Fortescue Mining Compensation Ruling
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition
Meta, U.S. States Discuss Settlement in Teen Addiction Trial
Google Changes EU Spam Policy Amid Antitrust Scrutiny
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’
Trump Administration Plans New Drug Pricing Deals With Biotech Firms
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation
PayPal Shares Sink as $50 Billion Takeover Bid Collapses
Tesla Raises Cybertruck Prices by $5,000 in US
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 



